10x Genomics (TXG) Operating Leases (2020 - 2026)
10x Genomics' Operating Leases history spans 6 years, with the latest figure at $73.4 million for Q4 2025.
- On a quarterly basis, Operating Leases changed 0.07% to $73.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73.4 million, a 0.07% change, with the full-year FY2025 number at $73.4 million, changed 0.07% from a year prior.
- Operating Leases hit $73.4 million in Q4 2025 for 10x Genomics, down from $87.0 million in the prior quarter.
- Over the last five years, Operating Leases for TXG hit a ceiling of $102.0 million in Q1 2023 and a floor of $66.3 million in Q1 2021.
- Historically, Operating Leases has averaged $83.6 million across 5 years, with a median of $84.9 million in 2023.
- Biggest five-year swings in Operating Leases: soared 41.65% in 2021 and later decreased 13.13% in 2025.
- Tracing TXG's Operating Leases over 5 years: stood at $76.8 million in 2021, then grew by 12.09% to $86.1 million in 2022, then dropped by 2.66% to $83.8 million in 2023, then decreased by 12.55% to $73.3 million in 2024, then increased by 0.07% to $73.4 million in 2025.
- Business Quant data shows Operating Leases for TXG at $73.4 million in Q4 2025, $87.0 million in Q3 2025, and $77.1 million in Q2 2025.